Pinnacle 21 Releases New PMDA, FDA, NMPA Validation Engines
Pinnacle 21 by Certara announces the latest Validation Engines for submissions to Japan PMDA, US…
Certara2024 年 4 月 23 日
Attain FDA Label Claims for Kinase Inhibitor Drugs with the Simcyp™ Simulator
Simcyp was used by pharma and biotech companies to inform, reduce and/or replace clinical studies…
Certara2023 年 12 月 6 日
SEND Dataset Quality Control: Best Practices & Recommendations
In this blog, Senior Product Management Director Peggy Zorn explores best practices & recommendations for…
Certara2023 年 4 月 25 日
Exceling at Accelerating in Rare Disease Drug Development
By: Rajesh Krishna, PhD, FAAPS and Steve Sibley According to the National Institutes of Health,…
Certara2023 年 1 月 26 日
New FDA Validator Rules V1.6 Explained
In this blog, we explore what you need to know about the update to the…
Certara2023 年 1 月 12 日
Certara Hosts Seminar on Drug Discovery Challenges in Japan and How Modeling and Simulation Can Solve Them
“Quantitative decision-making with data rather than empirical thinking" - Certara's Modeling & Simulation technology contributes…
Certara2022 年 9 月 13 日
New PMDA Validation Rules 3.0 Explained
In this blog, we explore what you need to know about the update to the…
Certara2022 年 3 月 2 日
The Challenging Road to Developing an Integrated Platform for Drug Discovery and Precision Medicine Using the Power of Pharmacometrics
We have often seen Dr. Hwi-yeol (Thomas) Yun, Associate Professor/Adjunct Professor at the College of…
Certara2022 年 2 月 7 日
Getting Results Faster – Supporting Physicians and Pharmacists with Biosimulation Technologies
Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and…
Certara2022 年 1 月 19 日
